XML 53 R14.htm IDEA: XBRL DOCUMENT v3.21.1

9 Investment in associate

12 Months Ended

Dec. 31, 2020

Disclosure of associates [abstract]

Investment in associate

9 Investment in associate

In connection with the corporate reorganization, described in Note 1 regarding the merger with BR Health, the Company acquired a 30% interest in UEPC, a medical school located in the Federal District, that offers higher education and post-graduate courses, both in person and long-distance learning. The Company’s interest in UEPC is accounted for using the equity method. The following table illustrates the summarized financial information of the Company’s investment in UEPC:

	December 31, 2020		December 31, 2019
Current assets	55,413		26,762
Non-current assets	82,575		77,031
Current liabilities	(34,531)		(29,328)
Non-current liabilities	(76,132)		(66,294)
Equity	27,325		8,171
Company’s share in equity – 30%	8,227		2,451
Goodwill	43,183		43,183
Carrying amount of the investment	51,410		45,634
Net revenue	113,965		85,816
Cost of services	(55,926)		(39,459)
General and administrative expenses	(27,341)		(29,476)
Finance result	(4,882)		(4,121)
Income before income taxes	25,816		12,760
Income taxes expenses	(252)		(2,275)
Net income for the year	25,564		10,485
Company’s share of income for the year	7,698		2,362
	December 31, 2020		December 31, 2019
Opening balance	45,634		-
Acquisition of minority interest (15%) in March 2019	-		24,458
Acquisition of additional minority interest (15%) in June 2019	-		24,457
Dividends receivable (included in Other assets)	(1,922)		(5,643)
Share of income	7,698		2,362
Closing balance	51,410		45,634

The Company tests at least annually the recoverability of the carrying amount of goodwill and there was no impairment for this goodwill.

X

- Definition

The disclosure of joint ventures. [Refer: Joint ventures [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2020-01-01
-Paragraph 17
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_17_b&doctype=Standard
-URIDate 2020-01-01

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2020-01-01
-Paragraph 16
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_16_b&doctype=Standard
-URIDate 2020-01-01

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2020-01-01
-Paragraph B4
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B4_b&doctype=Appendix&subtype=B
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_DisclosureOfJointVenturesExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration